These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 36835130)

  • 1. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.
    Kufe D
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.
    Hagiwara M; Yasumizu Y; Yamashita N; Rajabi H; Fushimi A; Long MD; Li W; Bhattacharya A; Ahmad R; Oya M; Liu S; Kufe D
    Cancer Res; 2021 Feb; 81(4):1111-1122. PubMed ID: 33323379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Hagiwara M; Fushimi A; Yamashita N; Bhattacharya A; Rajabi H; Long MD; Yasumizu Y; Oya M; Liu S; Kufe D
    Oncogene; 2021 Jul; 40(30):4930-4940. PubMed ID: 34163028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.
    Luan Z; Morimoto Y; Fushimi A; Yamashita N; Suo W; Bhattacharya A; Hagiwara M; Jin C; Kufe D
    Carcinogenesis; 2022 Feb; 43(1):67-76. PubMed ID: 34657147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells.
    Kufe DW
    J Cancer Metastasis Treat; 2022; 8():. PubMed ID: 35539431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.
    Bhattacharya A; Fushimi A; Yamashita N; Hagiwara M; Morimoto Y; Rajabi H; Long MD; Abdulla M; Ahmad R; Street K; Liu S; Liu T; Kufe D
    Mol Cancer Res; 2022 Apr; 20(4):556-567. PubMed ID: 35022313
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
    Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
    J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression.
    Yamashita N; Kufe D
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1-C drives stemness in progression of colitis to colorectal cancer.
    Li W; Zhang N; Jin C; Long MD; Rajabi H; Yasumizu Y; Fushimi A; Yamashita N; Hagiwara M; Zheng R; Wang J; Kui L; Singh H; Kharbanda S; Hu Q; Liu S; Kufe D
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
    Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
    Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
    Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.